Many of us were expecting Q1 to produce secondary
Post# of 72440
(Total Views: 138)
Posted On: 12/27/2017 11:16:59 AM
Many of us were expecting Q1 to produce secondary endpoint analyses of B-OM study and the top line results for P trial. I would like to add that I now believe Q1 will produce a major announcement regarding the availability of K in a pill form ready for testing on healthy people (as I believe that is the first test for the oral form of a product) to determine if body handles it well and flushes it in a timely manner from the body.
A deal is still the catalyst for immediate, rapid price gain but the progress of K in an oral form is the long term rocket building momentum for the advancement of K and that is the product that will take IPIX from a great investment to a possibly once in a lifetime investment. The safety and efficacy shown so far certainly leads me to believe we have a damned fine chance of having Kevetrin become the giant killer Dr Menon had envisioned it to become.
Best Christmas present ever!!!
A deal is still the catalyst for immediate, rapid price gain but the progress of K in an oral form is the long term rocket building momentum for the advancement of K and that is the product that will take IPIX from a great investment to a possibly once in a lifetime investment. The safety and efficacy shown so far certainly leads me to believe we have a damned fine chance of having Kevetrin become the giant killer Dr Menon had envisioned it to become.
Best Christmas present ever!!!
(6)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼